Trial · NCT03223337
Results by group540
Each measurement the trial posted, group by group, in the words and numbers it posted.
21 to 40 of 540
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Part 2: AUC (0-infinity) of GSK1278863 and Its Metabolites | Part 2: Mild Hepatic Impairment Participants | GSK2506102 (M5) | 19.4020 | Geometric Coefficient of Variation 36.6 | Hour*nanogram per milliliter |
| Part 2: AUC (0-infinity) of GSK1278863 and Its Metabolites | Part 2: Healthy Participants | GSK2506102 (M5) | 11.3374 | Geometric Coefficient of Variation 26.7 | Hour*nanogram per milliliter |
| Part 2: AUC (0-infinity) of GSK1278863 and Its Metabolites | Part 2: Mild Hepatic Impairment Participants | GSK2506104 (M3) | 91.7692 | Geometric Coefficient of Variation 41.0 | Hour*nanogram per milliliter |
| Part 2: AUC (0-infinity) of GSK1278863 and Its Metabolites | Part 2: Healthy Participants | GSK2506104 (M3) | 50.1154 | Geometric Coefficient of Variation 28.3 | Hour*nanogram per milliliter |
| Part 2: AUC (0-infinity) of GSK1278863 and Its Metabolites | Part 2: Mild Hepatic Impairment Participants | GSK2531398 (M6) | 41.4666 | Geometric Coefficient of Variation 31.2 | Hour*nanogram per milliliter |
| Part 2: AUC (0-infinity) of GSK1278863 and Its Metabolites | Part 2: Healthy Participants | GSK2531398 (M6) | 21.0066 | Geometric Coefficient of Variation 23.5 | Hour*nanogram per milliliter |
| Part 2: AUC (0-infinity) of GSK1278863 and Its Metabolites | Part 2: Mild Hepatic Impairment Participants | GSK2531401 (M13) | 46.7001 | Geometric Coefficient of Variation 66.5 | Hour*nanogram per milliliter |
| Part 2: AUC (0-infinity) of GSK1278863 and Its Metabolites | Part 2: Healthy Participants | GSK2531401 (M13) | 31.9797 | Geometric Coefficient of Variation 40.9 | Hour*nanogram per milliliter |
| Part 1: Percentage of AUC (0-infinity) Obtained by Extrapolation (Percentage AUCex) of GSK1278863 and Its Metabolites | Part 1: Moderate Hepatic Impairment Participants | GSK1278863 | 0.0463 | Standard Deviation 0.03971 | Percentage of AUCex |
| Part 1: Percentage of AUC (0-infinity) Obtained by Extrapolation (Percentage AUCex) of GSK1278863 and Its Metabolites | Part 1: Healthy Participants | GSK1278863 | 0.0486 | Standard Deviation 0.03445 | Percentage of AUCex |
| Part 1: Percentage of AUC (0-infinity) Obtained by Extrapolation (Percentage AUCex) of GSK1278863 and Its Metabolites | Part 1: Moderate Hepatic Impairment Participants | GSK2391220 (M2) | 0.1919 | Standard Deviation 0.14164 | Percentage of AUCex |
| Part 1: Percentage of AUC (0-infinity) Obtained by Extrapolation (Percentage AUCex) of GSK1278863 and Its Metabolites | Part 1: Healthy Participants | GSK2391220 (M2) | 0.4176 | Standard Deviation 0.38893 | Percentage of AUCex |
| Part 1: Percentage of AUC (0-infinity) Obtained by Extrapolation (Percentage AUCex) of GSK1278863 and Its Metabolites | Part 1: Moderate Hepatic Impairment Participants | GSK2487818 (M4) | 0.5756 | Standard Deviation 0.89564 | Percentage of AUCex |
| Part 1: Percentage of AUC (0-infinity) Obtained by Extrapolation (Percentage AUCex) of GSK1278863 and Its Metabolites | Part 1: Healthy Participants | GSK2487818 (M4) | 0.6763 | Standard Deviation 0.61031 | Percentage of AUCex |
| Part 1: Percentage of AUC (0-infinity) Obtained by Extrapolation (Percentage AUCex) of GSK1278863 and Its Metabolites | Part 1: Moderate Hepatic Impairment Participants | GSK2506102 (M5) | 0.6147 | Standard Deviation 0.17403 | Percentage of AUCex |
| Part 1: Percentage of AUC (0-infinity) Obtained by Extrapolation (Percentage AUCex) of GSK1278863 and Its Metabolites | Part 1: Healthy Participants | GSK2506102 (M5) | 2.1559 | Standard Deviation 2.01781 | Percentage of AUCex |
| Part 1: Percentage of AUC (0-infinity) Obtained by Extrapolation (Percentage AUCex) of GSK1278863 and Its Metabolites | Part 1: Moderate Hepatic Impairment Participants | GSK2506104 (M3) | NA | Standard Deviation NA | Percentage of AUCex |
| Part 1: Percentage of AUC (0-infinity) Obtained by Extrapolation (Percentage AUCex) of GSK1278863 and Its Metabolites | Part 1: Healthy Participants | GSK2506104 (M3) | NA | Standard Deviation NA | Percentage of AUCex |
| Part 1: Percentage of AUC (0-infinity) Obtained by Extrapolation (Percentage AUCex) of GSK1278863 and Its Metabolites | Part 1: Moderate Hepatic Impairment Participants | GSK2531398 (M6) | 0.2598 | Standard Deviation 0.10004 | Percentage of AUCex |
| Part 1: Percentage of AUC (0-infinity) Obtained by Extrapolation (Percentage AUCex) of GSK1278863 and Its Metabolites | Part 1: Healthy Participants | GSK2531398 (M6) | 0.3689 | Standard Deviation 0.26189 | Percentage of AUCex |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03223337/results?page=2